Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism

BACKGROUND: To optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.

AIM: To compare the effectiveness of restoring the quality of ejaculate in men receiving androgen replacement therapy (AZT) and patients receiving course combination therapy with testosterone and chorionic gonadotropin (AZT/HG).

MATERIALS AND METHODS: In observational prospective study was included 53 men observed at The National Medical Research Center for Endocrinology and AZT (n=19) or AZT/HG (n=34) more than 5 years, followed by stimulating gonadotropin therapy. The qualitative parameters of ejaculate were evaluated in all patients. The basic level of statistical significance was p<0,05.

RESULTS: The patient groups were comparable in age, BMI, duration of therapy used, type of testosterone preparation, as well as the etiology of hypogonadism. Sperm concentration in the AZT group there was a statistically significant negative dynamics, while in the ART/HG group, there were no statistically significant differences in the dynamics of sperm concentration. Statistically significant differences in the value of sperm concentration change were revealed. In both groups was observed statistically significant negative dynamics for sperm motility and morphology. There were no statistically significant differences in the value of changes motility and sperm morphology in both studied groups.

CONCLUSION: Course combination therapy with testosterone and chorionic gonadotropin is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy. For the restoration of sperm motility and morphology both methods do not show satisfactory results.

1. Ohlander SJ, Lindgren MC, Lipshultz LI. Testosterone and Male Infertility. Urologic Clinics of North America. 2016;43(2):195-202. doi: https://doi.org/10.1016/j.ucl.2016.01.006

2. Colpi GM, Francavilla S, Haidl G et al. European Academy of Andrology guideline Management of oligo-astheno-teratozoospermia. Andrology. 2018;6(4):513-524. doi: https://doi.org/10.1111/andr.12502

3. Rlsnet.ru [интернет]. Инструкция по применению к гонадотропину хорионическому. Доступ по ссылке https://www.rlsnet.ru/drugs/gonadotropin-xorioniceskii-5992

4. Vidal.ru [интернет]. Инструкция по применению к фоллитропину альфа. Доступ по ссылке https://www.vidal.ru/drugs/molecule/1279

5. WHO laboratory manual for the Examination and processing of human semen. Sixth edition, 2021. ISBN: 978 92 4 0030787

6. Hsieh T, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant Intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology. 2013;189:647–50. doi: https://doi.org/10.1016/j.juro.2012.09.043

7. Chen YW, Niu YH, Xu H, et al. Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study. Asian Journal of Andrology. 2019;21(4):413-418. doi: https://doi.org/10.4103/aja.aja_107_18

8. Shiraishi K, Ohmi C, Matsuyama H. Patient-reported outcomes and biochemical alterations during hormonal therapy in men with hypogonadotropic hypogonadism who have finished infertility treatment. Endocrine Journal. 2021;68(2):221-229. doi: https://doi.org/10.1507/endocrj.ej20-0365

9. Liu PY, Gebski VJ, Turner L et al. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Human Reproduction. 2002;17(3):625–33. doi: https://doi.org/10.1093/humrep/17.3.625

10. Fink J, Schoenfeld BJ, Hackney AC, Maekawa T, Horie S. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. Expert Review of Endocrinology Metabolism. 2021;16(1):1-8. doi: https://doi.org/10.1080/17446651.2021.1863783

11. Rastrelli G, Vignozzi L, Maggi M. Different medications for hypogonadotropic hypogonadism. Advanced Therapies in Pediatric Endocrinology and Diabetology. 2016;30:60–78. doi: https://doi.org/10.1159/000439332

12. Ortac M, Hidir M, Salabas E et al. Evaluation of gonadotropin-replacement therapy in male patients with hypogonadotropic hypogonadism. Asian Journal of Andrology. 2019;21(6):623-627. doi: https://doi.org/10.4103/aja.aja_6_19

13. Nieschlag E, Bouloux PG, Stegmann BJ et al. An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology. 2017;15(1). doi: https://doi.org/10.1186/s12958-017-0232-y

14. Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014;2(6):794-808. doi: https://doi.org/10.1111/andr.262

15. Kohn TP, Louis MR, Pickett SM et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertility and Sterility. 2017;107(2):351-357.e1. doi: https://doi.org/10.1016/j.fertnstert.2016.10.004

16. Almeida S, Rato L, Sousa M, Alves MG, Oliveira PF. Fertility and Sperm Quality in the Aging Male. Current Pharmaceutical Design. 2017;23(30):4429-4437. doi: https://doi.org/10.2174/1381612823666170503150313

17. Pohl E, Gromoll J, Wistuba J, Laurentino S. Healthy ageing and spermatogenesis. Reproduction. 2021;161(4):R89-R101. doi: https://doi.org/10.1530/REP-20-0633

18. Paoli D, Pecora G, Pallotti F, et al. Cytological and molecular aspects of the ageing sperm. Human Reproduction. 2019;34(2):218–227. doi: https://doi.org/10.1093/humrep/dey357

19. Khandwala YS, Baker VL, Shaw GM, et al. Association of Paternal Age With Perinatal Outcomes Between 2007 and 2016 in the United States: Population-based Cohort Study. Obstetric Anesthesia Digest. 2019;39(2):74-75. doi: https://doi.org/10.1097/01.aoa.0000557657.79785.e6